Apply to trial NCT06486142

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 3Drug trial

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening